Browsing Tag
Johnson & Johnson
102 posts
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.
Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit
Johnson & Johnson faces a new talc verdict in Philadelphia. Find out why even a small award still matters for investors and long-term strategy.
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
Johnson & Johnson’s AKEEGA clears major EU hurdle with CHMP nod for mHSPC BRCA mutation indication
Johnson & Johnson’s EU backing for AKEEGA’s expanded prostate cancer label could reshape its oncology strategy and precision medicine footprint in 2026.
J&J’s CAPLYTA nearly doubles remission rates in Phase 3 MDD trial
Find out how Johnson & Johnson’s CAPLYTA is redefining remission in depression with six-month data that could reshape MDD treatment benchmarks.
NYSE: JNJ Q4 earnings rise 49% to $2.10 EPS; oncology and neuroscience lead portfolio momentum
Johnson & Johnson posts $94.2B in 2025 revenue and sets $100.5B FY26 target. Find out what’s driving growth and how STELARA’s erosion could impact momentum.
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.
Can dual-targeting therapies redefine second-line colorectal cancer treatment in 2026?
Can dual-targeting therapies like amivantamab transform second-line colorectal cancer care? Explore what’s changing and who stands to win. Read the full story.
Johnson & Johnson colorectal cancer trial data reveal promising long-term efficacy of amivantamab-vmjw plus chemotherapy
Find out how Johnson & Johnson’s amivantamab‑vmjw plus chemotherapy shows durable response in metastatic colorectal cancer and what this means for future therapy.